ReviewStem cells and development2012
Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer.
Review in Stem cells and development, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.Journal of translational medicine · 2013Trial
- Stem cell therapy for hepatocellular carcinoma and end-stage liver disease.Journal of the Egyptian National Cancer Institute · 2023Review
- Continuous Flow Separation of Live and Dead Cells Using Gravity Sedimentation.Micromachines · 2023Article
- Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges.International journal of molecular sciences · 2023Review
- Therapeutic potential of dental pulp stem cells and their derivatives: Insights from basic research toward clinical applications.World journal of stem cells · 2022Review
- A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement.Molecular medicine reports · 2022Article
- The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype.Frontiers in oncology · 2022Review
- Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy.Frontiers in bioengineering and biotechnology · 2022Article
- Treating Metastatic Brain Cancers With Stem Cells.Frontiers in molecular neuroscience · 2021Review
- Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2.Stem cell research & therapy · 2020Article
- Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come?Frontiers in pharmacology · 2020Review
- Human Adipose-Derived Stem Cells Labeled with Plasmonic Gold Nanostars for Cellular Tracking and Photothermal Cancer Cell Ablation.Plastic and reconstructive surgery · 2017Article
- Mesenchymal Stromal/Stem Cells: A New Era in the Cell-Based Targeted Gene Therapy of Cancer.Frontiers in immunology · 2017Review
- Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.Stem cells and development · 2016Article
- Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses.Innovative surgical sciences · 2016Article
- Mesenchymal stem cell: a new horizon in cancer gene therapy.Cancer gene therapy · 2016Review
- Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases.Journal of experimental & clinical cancer research : CR · 2015Article
- Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?Clinical and experimental medicine · 2014Review
- Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment.Cancer research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem (or stromal) cells (MSCs) are nonhematopoietic progenitor cells that can be obtained from bone marrow aspirates or adipose tissue, expanded and genetically modified in vitro, and then used for cancer therapeutic strategies in vivo. Here, we review available data regarding the application of MSC-based tumor-targeted therapy in gastrointestinal cancer, provide an overview of the general history of MSC-based gene therapy in cancer research, and discuss potential problems associated with the utility of MSC-based therapy such as biosafety, immunoprivilege, transfection methods, and distribution in the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.